SIGNS AGREEMENT WITH THE NATIONAL RESEARCH COUNCIL OF CANADA FOR CANNABINOID BIOFERMENTATION PROCESS DEVELOPMENT AND SCALE-UP
Inmed Pharmaceuticals Inc. (IN.T) has entered into a research agreement with the National Research Council of Canada (NRC) in Montreal, Canada, for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli.
Inmed's vice-president, preclinical research and development, Dr. Eric Hsu, PhD, commented: "The NRC has significant biofermentation expertise and extensive facilities to support Inmed's scale-up activities. The NRC will help us define specific process parameters to improve fermentation scale and product yield needed for Inmed to maximize the commercial potential of our proprietary E.coli-based cannabinoid biosynthesis system. This work is the natural progression of several years [of] history in designing cannabinoid-specific vectors at the University of British Columbia and the next step in reaching our goal of establishing a leadership position in the field of cannabinoid biosynthesis."
About Inmed Pharmaceuticals Inc.
Inmed is a preclinical-stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. Inmed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the company.